Skip to content

Allen & Overy on the combination between Biolog-id and SPAC Genesis Growth Tech Acquisition Corp

Related people
Thebault Olivier
Olivier Thebault

Partner

Paris

View profile →

Ancel Alexandre
Alexandre Ancel

Partner

Paris

View profile →

Payelle Anne-Caroline
Anne-Caroline Payelle

Counsel

Paris

View profile →

Billere-Mellet Jade
Jade Billere-Mellet

Associate

Paris

View profile →

Image of Myriam Azmy
Myriam Azmy

Associate

Paris

View profile →

Press contacts

For media enquiries relating to this topic, please contact:

Amelie Gillot

Communications officer

Paris

View profile →

12 September 2022

Allen & Overy has advised Genesis Growth Tech Acquisition Corp, a Nasdaq-listed Special Purpose Acquisition Company ("SPAC"), in connection with the negotiation of a Business Combination Agreement relating to a proposed merger with Biolog-id, a global leader in the development and service of identification and traceability solutions for blood products and injectable therapeutic preparations in oncology.

This merger will create a publicly traded digital health solutions company focused on value chain optimization.

The transaction values Biolog-id at $312 million and is scheduled for the first quarter of 2023. Following the merger, Biolog-id will be listed on Nasdaq under the symbol “BGID”.

The Allen & Overy team in Paris was composed of Olivier Thébault (Partner), Alexandre Ancel (Partner), Anne-Caroline Payelle (Counsel), Jade Billère-Mellet and Myriam Azmy (Associates).